Late breaking poster presentation highlights
Revian's patented combination of wavelengths has been shown to
reduce Dihydrotestosterone production by 74%
MORRISVILLE, N.C., May 14, 2024
/PRNewswire/ -- REVIAN Inc., an aesthetic medical technology
company using precise wavelengths of LED light to rejuvenate hair
and skin, announced an upcoming presentation at the 2024 Society
for Investigative Dermatology Annual Meeting being held in
Dallas on May 15-18, 2024. Dr. Jacob Kocher will deliver a poster presentation
of data illustrating that Revian's patented combination of
wavelengths reduces Dihydrotestosterone (DHT) production by 74%, a
95% improvement over industry standard finasteride, which reduced
DHT production by 38%, at 24 hours post treatment, in the same
in vitro experiment. DHT plays an important causative
role in pattern hair loss (androgenic alopecia or pattern
baldness).
Presentation Details:
Poster Title: Inhibition of
dihydrotestosterone (DHT) formation via dual wavelength orange-red
light production of nitric oxide
Category: Translational Studies and Early Preclinical to
Clinical
Session: Poster only
Session Date and Time: May 17th, 4:00-6:00 PM
Location: Trinity Exhibit Hall, Hilton Anatole, Dallas
"These tests prove Revian's proprietary combination of 620 nm
and 660 nm wavelengths block DHT production at a greater rate than
the industry standard Finasteride. This is a major breakthrough for
hair loss research." stated John Oakley, Chief Executive
Officer of Revian. "Having an alternative to a systemic drug with
serious side effects is a massive improvement to the available
treatment options for anyone seeking a more healthy solution to
stopping hair loss."
More information on the 2024 Society for Investigative
Dermatology Annual Meeting can be found here.
About the Revian Red Hair Growth System
The REVIAN RED
System is an FDA cleared, lightweight wireless cap controlled by a
mobile App that functions to provide a hair loss treatment for men
and women using precision LED light. The device's patented dual
wavelength LED technology provides broader scalp coverage and
better skin penetration, producing the best clinical trial
performance of any hair rejuvenation treatment available on the
market. REVIAN RED uses a patented combination of two wavelengths
of light to stimulate the production and release of nitric oxide,
which is proven to increase local blood flow, reduce inflammation,
and inhibit DHT production. This provides the right environment for
new hair growth. REVIAN RED's cleared indication for use is the
treatment of androgenetic alopecia, to promote hair growth in males
who have Norwood-Hamilton classifications of IIa-V patterns of
hair loss and to treat androgenetic alopecia and to promote hair
growth in females who have Ludwig-Savin Scale I-1 to II-4, II1, II2
or frontal patterns of hair loss; both with Fitzpatrick Skin Types
I-IV.
About Revian, Inc.
Revian, an operating subsidiary of
KNOW Bio, LLC, is an aesthetic medical technology innovator
dedicated to stimulating the body's natural processes to rejuvenate
hair and skin with light. The company creates products that deliver
precise wavelengths of light and allow people to experience its
regenerative potential in the convenience of their own homes.
Revian is committed to partnering with health-care providers, and
other caring professionals, to deliver meaningful results, backed
by scientific data. For more information visit www.revian.com.
Contact:
John
Oakley
REVIAN, Inc.
joakley@revian.com
919-939-7715
View original content to download
multimedia:https://www.prnewswire.com/news-releases/revian-announces-poster-presentation-at-2024-society-for-investigative-dermatology-annual-meeting-302145249.html
SOURCE REVIAN, Inc.